In this episode, guest Joseph F. Merola, MD, discusses the results of the TOGETHER-PsA trial and explores combination therapy as an integrated approach to psoriatic arthritis (PsA) management.

· What is the role of obesity in PsA? 0:55

· Dr. Merola discusses findings from the TOGETHER-PsA trial. 2:11

· Is the difference clinically meaningful to you as a rheumatologist? 4:16

· For patients today, would you combine tirzepatide with ixekizumab as a form of standard care? 5:13

Joseph Merola, MD, MMSc, is professor and chair of the department of dermatology, professor of internal medicine in the division of rheumatic diseases and professor in the UT Southwestern O’Donnell School of Public Health. We’d love to hear from you! Send your comments/questions to Dr. Gelfand at [email protected]. Follow Dr. Gelfand on LinkedIn. Dr. Merola can be reached at [email protected]. For more, be sure to visit the Beneath the Surface video blog on Healio.com.

Disclosures: Eli Lilly sponsored TOGETHER-PsA. Gelfand is Chief Medical Editor of Healio Dermatology. Merola reports receiving consultant fees from AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Incyte, Janssen, Leo Pharma, MoonLake Immunotherapeutics, Novartis, Pfizer, Sanofi-Regeneron and UCB; and grant or research support from Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, MoonLake Immunotherapeutics, Sanofi-Regeneron, Sun Pharma and UCB.

References:

· Merola JF, et al. Arthritis Rheumatol. 2026;doi:10.1002/art.70134.

· Merola JF, et al. Late-breaking research: Session 2. Presented at: American Academy of Dermatology Annual Meeting; March 27-31, 2026; Denver.